A Phase I Open-label, Multicenter Dose Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of PLB1001 in Patients With Met-positive (Met+) Advanced Non-small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2017
At a glance
- Drugs Bozitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; First in man
- Sponsors Beijing Pearl Biotechnology
- 16 Oct 2017 Last checked against ClinicalTrials.gov record.
- 10 Oct 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2018.
- 28 Sep 2016 New trial record